cvd
Study finds new test could better predict risk of heart disease
April 28, 2025Research and Development Cardiology, Chalmers University of Technologyu, Harvard, cholesterol tests, cvd
A study by Harvard University, US, and Chalmers University of Technology, Sweden, has found that measuring a lipoprotein marker combination …
Bayer and Evotec to collaborate on precision cardiology
April 30, 2024Research and Development Bayer, Cardiology, cardio, cvd
Bayer and Evotec have announced that they have updated the focus of their collaboration to work on the development of …
Novo Nordisk’s Wegovy reduces risk of cardiovascular events
August 9, 2023Research and Development Cardiology, Novo Nordisk, Wegovy, cardiovascular, cvd, semaglutide
Novo Nordisk has shared results from the SELECT cardiovascular outcomes trial, which show that a once weekly subcutaneous dose of …
Evox Therapeutics enters agreement for next generation gene therapy for heart disease
August 4, 2023Research and Development Cardiology, Evox Therapeutics, Icahn Mount Sinai, cvd, gene therapy
Evox Therapeutics has announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn …
Ionis and Novartis partner for CVD treatment programme
August 4, 2023Business Services Cardiology, Ionis Pharmaceuticals, License Agreement, Novartis, cvd
Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement with Novartis, aiming to discover, …
American Heart Association awards $2.1m to research link between migraine, strokes and CVD
July 27, 2023Research and Development American Heart Association, Cardiology, cvd, migraine, stroke
The American Heart Association has announced that it will fund seven new scientific research studies to learn more about the …
AstraZeneca’s Farxiga approved to reduce risk of cardiovascular death
May 9, 2023Medical Communications AstraZeneca, Cardiology, FDA, cvd, farxiga, heart failure
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Farxiga to reduce the risk of cardiovascular …
Significant lack of women and minorities involved in clinical trials for cardiometabolic medication, research shows
June 1, 2020Sales and Marketing cardio, cardiovascular, cvd
Women and minorities, particularly African Americans, continue to be under represented in clinical trials for cardiometabolic medication, according to a …
Positive CHMP recommendation for Sanofi’s atherosclerotic CVD drug Praluent
February 4, 2019Sales and Marketing Europe, atherosclerotic cardiovascular disease, cvd, pharma, praluent
It has been announced that Sanofi’s Praluent (alirocumab) has been awarded a positive recommendation from the European Medicines Agency’s Committee …
The new and improved Spring 2018 edition of Pharmafile is available to read online now!
May 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CNS, Cancer, Pharmafocus, cardiovascular, cvd, oncology, pharmafile
The Spring 2018 edition of Pharmafile, our long-running bi-annual guide to the latest trends, projections and thought leadership positions in …
Eli Lilly partners with Chinese institution to advance the nation’s diabetes and CVD care
April 27, 2018Medical Communications, Research and Development China, Eli Lilly, cardiovascular disorders, cvd, diabetes, pharma, type 2 diabetes
EIi Lilly has announced plans to partner up with China’s National Center for Cardiovascular Diseases (NCCD), the nation’s institution responsible …
NHS looks to ESC for next-gen heart drug data
August 28, 2015Medical Communications, Research and Development ALN-PCScs, Repatha, alirocumab, cardiology, cardiovascular disease, cvd, evolocumab, heart disease, high cholesterol, praluent
New data is expected to be presented at the European Cardiology Society congress in London, on the high cholesterol drugs …
BMS enters gene therapy development deal
April 7, 2015Research and Development BMS, Bristol-Myers Squibb, R&D, cardiovascular disease, cvd, heart disease, heart failure, uniQure
Bristol-Myers Squibb (BMS) has signed a multi-million dollar agreement with Amsterdam-based gene therapy firm uniQure to boost research into new …
NICE: ‘Use more statins’
February 12, 2014Sales and Marketing NHS, NICE, baker, cvd, statins
NICE has decided more NHS patients ought to be considered at risk of cardiovascular disease (CVD) – and therefore advises …
